Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
Peng Yuan, Xichun Hu, Tao Sun, et al.
European Journal of Cancer (2019) Vol. 112, pp. 57-65
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Breast cancer: an up‐to‐date review and future perspectives
Ruoxi Hong, Binghe Xu
Cancer Communications (2022) Vol. 42, Iss. 10, pp. 913-936
Open Access | Times Cited: 196
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Hope S. Rugo, Aditya Bardia, Frederik Marmé, et al.
The Lancet (2023) Vol. 402, Iss. 10411, pp. 1423-1433
Open Access | Times Cited: 195
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Hope S. Rugo, Aditya Bardia, Frederik Marmé, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 29, pp. 3365-3376
Closed Access | Times Cited: 192
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1709-1718
Open Access | Times Cited: 122
TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, Aditya Bardia, Sara M. Tolaney, et al.
Future Oncology (2020) Vol. 16, Iss. 12, pp. 705-715
Open Access | Times Cited: 106
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
Jieqiong Liu, Ying Wang, Zhenluan Tian, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 61
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Zefei Jiang, Erwei Song, Cuizhi Geng, et al.
Translational Breast Cancer Research (2022) Vol. 3, pp. 13-13
Open Access | Times Cited: 56
Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study
Jiayu Wang, Yunjiang Liu, Qingyuan Zhang, et al.
Cancer Communications (2024) Vol. 44, Iss. 7, pp. 833-851
Open Access | Times Cited: 9
Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment
Badrul Islam, Maryam B. Lustberg, Nathan P. Staff, et al.
Journal of the Peripheral Nervous System (2019) Vol. 24, Iss. S2
Closed Access | Times Cited: 59
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT
Yihui Zhu, Zhonghua Tao, Ying Chen, et al.
Breast Cancer Research and Treatment (2022) Vol. 193, Iss. 1, pp. 65-81
Open Access | Times Cited: 34
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Binghe Xu, Shusen Wang, Min Yan, et al.
Nature Medicine (2024)
Open Access | Times Cited: 4
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study
Ying Fan, Qingyuan Zhang, Min Yan, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial
Niels A.D. Guchelaar, Ron H.J. Mathijssen, Maaike de Boer, et al.
EClinicalMedicine (2025) Vol. 80, pp. 103065-103065
Closed Access
MMP1-induced NF-κB activation promotes epithelial–mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer
Letian Chen, Yinghuan Cen, Keyang Qian, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States
Sara M. Tolaney, Kevin Punie, Lisa A. Carey, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103691-103691
Open Access | Times Cited: 3
Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)
Zefei Jiang, Erwei Song, Xiaojia Wang, et al.
Translational Breast Cancer Research (2020) Vol. 1, pp. 27-27
Open Access | Times Cited: 24
A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
Bingyue Liu, Lei Liu, Jianmin Ran, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101563-101563
Open Access | Times Cited: 9
Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products
April L. Risinger, Lin Du
Natural Product Reports (2019) Vol. 37, Iss. 5, pp. 634-652
Open Access | Times Cited: 25
<p>Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer</p>
Jinhong Shi, Feiqi Liu, Yanqiu Song
Cancer Management and Research (2020) Vol. Volume 12, pp. 9375-9387
Open Access | Times Cited: 22
Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
Shuanghe Li, Chongyang Bao, Lingli Huang, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6021-6021
Open Access | Times Cited: 12
Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
Hanfang Jiang, Huiping Li, Guohong Song, et al.
Breast Cancer Research and Treatment (2023) Vol. 199, Iss. 1, pp. 67-79
Open Access | Times Cited: 6
A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
Jiayi Huang, Xiaofeng Xie, Xuelian Chen, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
Demin Shi, Yan Li, Xueyan Liang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial
Mengru Cao, Hailing Lü, Yan Shi, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis
Kaniz Afroz Tanni, Bang Truong, Brandon Johnson, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 163, pp. 103375-103375
Closed Access | Times Cited: 13
Page 1 - Next Page

Scroll to top